298 related articles for article (PubMed ID: 28871852)
1. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.
Wasserman RL
Immunotherapy; 2017 Sep; 9(12):1035-1050. PubMed ID: 28871852
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
Wasserman RL; Melamed I; Kobrynski L; Puck J; Gupta S; Doralt J; Sharkhawy M; Engl W; Leibl H; Gelmont D; Yel L
Immunotherapy; 2016 Oct; 8(10):1175-86. PubMed ID: 27468136
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
[TBL] [Abstract][Full Text] [Related]
4. Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders.
Sanford M
BioDrugs; 2014 Aug; 28(4):411-20. PubMed ID: 24925799
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
[TBL] [Abstract][Full Text] [Related]
6. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.
Wasserman RL
Immunotherapy; 2014; 6(5):553-67. PubMed ID: 24896624
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model.
Kang DW; Jadin L; Nekoroski T; Drake FH; Zepeda ML
Drug Deliv Transl Res; 2012 Aug; 2(4):254-64. PubMed ID: 25787031
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
9. In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins.
Leidenmühler P; Höfinghoff J; Haider N; Brachtl G; Weiller M; Bilic I; Gangadharan B
Drug Deliv Transl Res; 2023 Sep; 13(9):2367-2377. PubMed ID: 36920736
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
Shapiro R
Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
[TBL] [Abstract][Full Text] [Related]
11. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.
Wasserman RL
J Clin Immunol; 2012 Dec; 32(6):1153-64. PubMed ID: 22828788
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
13. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H
Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032
[TBL] [Abstract][Full Text] [Related]
15. 7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.
Shapiro RS; Borte M
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):86. PubMed ID: 25546773
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
Shapiro RS
Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
[TBL] [Abstract][Full Text] [Related]
17. 7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.
Shapiro RS; Borte M
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):65-6. PubMed ID: 25546766
[TBL] [Abstract][Full Text] [Related]
18. Intravenous and subcutaneous immunoglobulin G replacement therapy.
Bonilla FA
Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
[TBL] [Abstract][Full Text] [Related]
19. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
20. ENHANZE
Locke KW; Maneval DC; LaBarre MJ
Drug Deliv; 2019 Dec; 26(1):98-106. PubMed ID: 30744432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
